These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 35756846

  • 1. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
    Luong TT, Powers CN, Reinhardt BJ, Weina PJ.
    Curr Res Pharmacol Drug Discov; 2022; 3():100112. PubMed ID: 35756846
    [Abstract] [Full Text] [Related]

  • 2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE, Ahern D, Scatina J, Kao J.
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [Abstract] [Full Text] [Related]

  • 3. Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan.
    Luong TT, McAnulty MJ, Evers DL, Reinhardt BJ, Weina PJ.
    Curr Res Toxicol; 2021 Jun; 2():217-224. PubMed ID: 34345864
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L, Riesenman C, Lam YW.
    Clin Pharmacokinet; 1995 Jun; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
    Baumann P, Rochat B.
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
    [Abstract] [Full Text] [Related]

  • 12. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J.
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [Abstract] [Full Text] [Related]

  • 13. Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions.
    Mannheimer B, Wettermark B, Lundberg M, Pettersson H, von Bahr C, Eliasson E.
    Br J Clin Pharmacol; 2010 Apr; 69(4):411-7. PubMed ID: 20406225
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Are pharmacokinetic drug interactions with the SSRIs an issue?
    Brøsen K.
    Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Systematic review and guide to selection of selective serotonin reuptake inhibitors.
    Edwards JG, Anderson I.
    Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.